Literature DB >> 9679896

Influence of radical prostatectomy on serum hormone levels.

L R Miller1, A W Partin, D W Chan, D J Bruzek, A S Dobs, J I Epstein, P C Walsh.   

Abstract

PURPOSE: The influence of radical prostatectomy on the hypothalamic pituitary axis has not been well studied. It is also unclear how alterations in serum androgen levels that result from surgical removal of the prostate might influence the recovery of libido and sexual function following radical prostatectomy. We determined the influence of radical prostatectomy on the hypothalamic pituitary testicular axis of 63 men with clinically localized prostate cancer treated only with radical prostatectomy.
MATERIALS AND METHODS: A total of 63 healthy men 43 to 67 years old were enrolled in this prospective study. Phlebotomy was performed immediately before and 1 year following radical retropubic prostatectomy. Sera were stored frozen and analyzed as a group at the end of the study. We measured serum testosterone, percent free testosterone, dihydrotestosterone (DHT), estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone binding globulin and prolactin.
RESULTS: Following radical prostatectomy there was a statistically significant increase in serum testosterone, free testosterone, estradiol, LH and FSH (p <0.0001), and statistically significant decrease in serum DHT (p <0.0001). No difference was noted in serum sex hormone binding globulin or prolactin levels. There was no statistically significant correlation between any serum hormone and sample storage time, patient age or prostate volume that could limit potential bias in study design. Serum hormone changes did not correlate with pathological stage or histological grade for this group of patients.
CONCLUSIONS: Radical prostatectomy influences the hypothalamic pituitary axis by increasing serum testosterone, percent free testosterone, estradiol, LH and FSH while decreasing serum DHT levels. These findings suggest that the sexual dysfunction associated with radical prostatectomy cannot be explained by androgen deficiency alone. These data further suggest that the normal prostate and/or prostate neoplasm could secrete a substance or substances that give negative feedback control to pituitary gonadotropin secretion. Further investigation is warranted to identify this substance or substances.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679896

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Testosterone deficiency syndrome and prostate cancer: illustrative annotations for a debate.

Authors:  Alvaro Morales; Angela Black
Journal:  Can Urol Assoc J       Date:  2008-02       Impact factor: 1.862

3.  Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study.

Authors:  Yi X Chan; Matthew W Knuiman; Mark L Divitini; David J Handelsman; John P Beilby; Bu B Yeap
Journal:  Horm Cancer       Date:  2018-08-10       Impact factor: 3.869

4.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

Review 5.  Androgen action in prostate cancer.

Authors:  Sujit Basu; Donald J Tindall
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

6.  Androgen replacement therapy after prostate cancer treatment.

Authors:  Mohit Khera
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

7.  Androgen replacement therapy in the aging male.

Authors:  Jeremy B Myers; Randall B Meacham
Journal:  Rev Urol       Date:  2003

8.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

9.  Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Giulia Castagna; Maria Chiara Clementi; Alberto Briganti; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2013-01-03       Impact factor: 4.226

10.  Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.

Authors:  Phillip M Pierorazio; Luigi Ferrucci; Anna Kettermann; Dan L Longo; E Jeffrey Metter; H Ballentine Carter
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.